非布索坦进医保了没？

The State Food and Drug Administration of China issued a new drug certificate for (Febuxostat) to Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. on June 26, 2013. The approved products are 40mg×16 tablets/box and 80mg×6 tablets/box. On June 26, 2013, the imported original drug Febuxostat (Febuxostat) was officially launched in China. Febuxostat (Febuxostat) has been included in the national medical insurance, No. 911, the drug name is Febuxostat, the dosage form is oral sustained-release dosage form, the drug category is musculo-skeletal system drugs > anti-gout drugs (XM>

Febuxostat (Febuxostat) has become a new first-line product for the treatment of gout due to its quick effects and few side effects. Due to the high price of Febuxostat (Febuxostat) in China, many patients can only stay away. According to Medical Travel, Febuxostat (Febuxostat) produced by Zydus Pharmaceutical Factory in India has the same efficacy as the original drug, but the price is indeed much lower. The specification is 80mg*30 tablets/box. Its price is about 200$. Due to the floating exchange rate, the price cannot be accurate. Please consult Medical Companion Travel for specific prices.

On the clinical side, if a patient is found to have abnormal liver function (ALT more than 3 times the upper limit of the reference range), the medication should be discontinued and investigated to determine the possible cause. Febuxostat should not be reinstituted in these patients who have abnormal liver function tests and no other reasonable explanation. If the patient's serum ALT exceeds more than 3 times the reference range, and the serum total bilirubin exceeds more than 2 times the reference range, and other causes are excluded, the patient is at risk of severe drug-induced liver damage, and these patients should not resume using Febuxostat (Febuxostat). For those patients whose serum ALT or bilirubin elevations are small and have other reasonable explanations, treatment with febuxostat (febuxostat) should be used with caution. Secondary Hyperuricemia There are no studies on the use of this product in patients with secondary hyperuricemia (including organ transplant recipients). Therefore, it is not recommended to use this product in patients with large increases in urate (such as malignant diseases, Lesch-Nyhan syndrome).

The above is the medical insurance situation for (febuxostat) provided by our medical companion travel. If you have any other questions, please consult the medical companion travel service.

Related hot article recommendations: